

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



**Bloomage BioTechnology Corporation Limited**  
**華熙生物科技股份有限公司**  
*(incorporated in the Cayman Islands with limited liability)*  
**(Stock Code: 00963)**

**VOLUNTARY DISCLOSURE**  
**ACQUISITION OF INTEREST BY DIRECTORS**

Ms. Zhao had acquired on-market an aggregate of 890,000 Shares in a series of transactions conducted on 10 September 2014 to 12 September 2014, 15 September 2014 to 19 August 2014 and 22 September 2014, representing approximately 0.27% of the issued share capital of the Company as at the date of this announcement. Further, Mr. Jin had acquired on-market an aggregate of 290,000 Shares in a series of transactions conducted on 15 September 2014, 17 September 2014, 18 September 2014 and 22 September 2014, representing approximately 0.09% of the issued share capital of the Company as at the date of this announcement. Consequently, Ms. Zhao and Mr. Jin beneficially held a total of 193,370,000 Shares and 33,800,000 Shares respectively, representing approximately 58.24% and 10.18% of the issued share capital of the Company respectively as at the date of this announcement.

This announcement is made voluntarily by Bloomage BioTechnology Corporation Limited (the “**Company**”).

The Company has been informed by Ms. Zhao Yan, the chairman of the Board and an executive Director (“**Ms. Zhao**”), that Ms. Zhao had acquired on market an aggregate of 890,000 shares of the Company (the “**Shares**”) in a series of transactions conducted on 10 September 2014 to 12 September 2014, 15 September 2014 to 19 August 2014 and 22 September 2014, representing approximately 0.27% of the issued share capital of the Company as at the date of this announcement (the “**Acquisition of Ms. Zhao**”).

The Company has also been informed by Mr. Jin Xuekun, the chief executive officer of the Company and an executive Director (“**Mr. Jin**”), that Mr. Jin had acquired on market an aggregate of 290,000 Shares in a series of transactions conducted on 15 September 2014, 17 September 2014, 18 September 2014 and 22 September 2014, representing approximately 0.09% of the issued share capital of the Company as at the date of this announcement (the “**Acquisition of Mr. Jin**”).

After the Acquisition of Ms. Zhao and the Acquisition of Mr. Jin and as at the date of this announcement, Ms. Zhao and Mr. Jin beneficially held a total of 193,370,000 Shares and 33,800,000 Shares respectively, representing approximately 58.24% and 10.18% of the issued share capital of the Company respectively.

By order of the Board  
**Bloomage BioTechnology Corporation Limited**  
**ZHAO YAN**  
*Chairman*

Hong Kong, 22 September 2014

*As at the date of this announcement, the executive directors of the Company are Ms. Zhao Yan, Mr. Jin Xuekun, Ms. Liu Aihua and Ms. Wang Aihua; the non-executive director is Mr. Guo Jiajun; the independent non-executive directors are Ms. Zhan Lili, Mr. Hai Wen and Mr. Li Junhong.*